Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Friedreich Ataxia: early-phase trial registry
7 of 15 indexed Friedreich Ataxia trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,140 of 28,707 conditions by registered trial count.
15 US clinical trials · 7 currently recruiting · #1,140 of 28,707 conditions by registered trial count
Friedreich Ataxia: 15 US clinical trials tracked, 7 recruiting.
Friedreich Ataxia is the subject of 15 registered US clinical trials on ClinicalTrials.gov, 7 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most active sponsor is Biogen, running 4 of these trials.
Enrollment posture brief
Registry condition friedreich-ataxia
OPEN 7 | RECR 47% | LATE 2 | EARLY 5 | RANK #1140 | SPON 4
Volume-matched condition peers
Nearest open-share peer: Autism (47% recruiting · 105 trials)
Friedreich Ataxia lists 7 open slots (47% of 15 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Friedreich Ataxia on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Friedreich Ataxia recruits in line with its size-band peers.
7 of 15 indexed trials (46.7%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Friedreich Ataxia research.
Biogen accounts for 4 of 15 trials (26.7%). 10 distinct sponsors appear on at least one study for this condition label.
-
Most Friedreich Ataxia trials plan to enrol fewer than 100 people.
Median target enrolment is 65 among the 15 trials that report a genuine target (sentinel values excluded). 9 of those (60%) plan for fewer than 100 participants.
-
Friedreich Ataxia splits between interventional and observational designs.
7 interventional and 8 observational studies make up this index (46.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
15 total, page 1 of 1
Friedreich Ataxia Global Clinical Consortium UNIFIED Natural History Study
Friedreich's Ataxia Research Alliance
NCT06016946
A Study to Learn More About the Long-Term Safety of BIIB141 (Omaveloxolone) in Participants With Friedreich's Ataxia Who Are Prescribed it by Their Own Doctors
Biogen
NCT06623890
A Study to Learn More About the Effects and Long-Term Safety of BIIB141 (Omaveloxolone) in Participants With Friedreich's Ataxia Aged 2 to 15 Years Old (BRAVE)
Biogen
NCT06953583
Clinical Course Of Disease In Participants With FA-CM
Lexeo Therapeutics
NCT06865482
A Study to Find Out How BIIB141 (Omaveloxolone) is Processed in the Body and to Learn More About Its Safety in Participants With Friedreich's Ataxia Aged 2 to 15 Years Old
Biogen
NCT06054893
Phase IA and IB Study of AAVrh.10hFXN Gene Therapy for the Cardiomyopathy of Friedreich's Ataxia
Weill Medical College of Cornell University
NCT05302271
A Study to Learn How BIIB141 (Omaveloxolone) Affects the Health of Participants With Friedrich's Ataxia Who Took it During Pregnancy and/or During Breastfeeding and About the Health of Their Babies
Biogen
NCT06628687
FA Clinical Outcome Measures
Friedreich's Ataxia Research Alliance
NCT03090789
A Natural History Study to TRACK Brain and Spinal Cord Changes in Individuals with Friedreich Ataxia (TRACK-FA)
Monash University
NCT04349514
A Study to Assess the Safety and Efficacy of Vatiquinone in Participants With Friedreich Ataxia
PTC Therapeutics
NCT05515536
Gene Therapy for Cardiomyopathy Associated With Friedreich's Ataxia
Lexeo Therapeutics
NCT05445323
Early and Longitudinal Assessment of Neurodegeneration in the Brain and Spinal Cord in Friedreich's Ataxia
University of Minnesota
NCT01776164
Study to Evaluate Multiple Ascending Dose and Multi-Dose of DT-216 in Adult Patients With Friedreich Ataxia
Design Therapeutics
NCT05573698
A Double-Blind, Placebo-Controlled, Dose Exploration Study of CTI-1601 in Adult Subjects With Friedreich's Ataxia
Larimar Therapeutics
NCT05579691
Measurement of Frataxin mRNA in Biofluids
University of Florida
NCT06496451
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
| Phase 2 | 1 |
| Phase 3 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Friedreich Ataxia records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Friedreich Ataxia trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Friedreich Ataxia page
15 registered trials, 7 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 7 Friedreich Ataxia trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Biogen sponsors the most Friedreich Ataxia trials on record, review their full trial history before evaluating a specific study. See Biogen's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Friedreich Ataxia condition card totals 15 registered trials; most-linked intervention Omaveloxolone; top US site state Florida. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.